Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EXclusion of non-Involved uterus from the Target Volume (EXIT-trial): an individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques.
Vandecasteele K, Tummers P, Van Bockstal M, De Visschere P, Vercauteren T, De Gersem W, Denys H, Naert E, Makar A, De Neve W. Vandecasteele K, et al. BMC Cancer. 2018 Sep 17;18(1):898. doi: 10.1186/s12885-018-4800-0. BMC Cancer. 2018. PMID: 30223802 Free PMC article. Clinical Trial.
Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001).
Ost P, Fonteyne V, De Neve W, De Gersem W, De Wagter C, Vandecasteele K, Duprez F, De Meerleer G. Ost P, et al. Among authors: vandecasteele k. Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1286; author reply 1287. doi: 10.1016/j.ijrobp.2008.12.008. Int J Radiat Oncol Biol Phys. 2009. PMID: 19251105 No abstract available.
Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.
Vandecasteele K, De Neve W, De Gersem W, Delrue L, Paelinck L, Makar A, Fonteyne V, De Wagter C, Villeirs G, De Meerleer G. Vandecasteele K, et al. Strahlenther Onkol. 2009 Dec;185(12):799-807. doi: 10.1007/s00066-009-1986-8. Strahlenther Onkol. 2009. PMID: 20013089
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.
De Meerleer G, Vandecasteele K, Ost P, Delrue L, Denys H, Makar A, Speleers B, Van Belle S, Van den Broecke R, Fonteyne V, De Neve W. De Meerleer G, et al. Among authors: vandecasteele k. Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):775-81. doi: 10.1016/j.ijrobp.2009.11.039. Epub 2010 Apr 24. Int J Radiat Oncol Biol Phys. 2011. PMID: 20421155
Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients.
Dehing-Oberije C, De Ruysscher D, Petit S, Van Meerbeeck J, Vandecasteele K, De Neve W, Dingemans AM, El Naqa I, Deasy J, Bradley J, Huang E, Lambin P. Dehing-Oberije C, et al. Among authors: vandecasteele k. Radiother Oncol. 2010 Dec;97(3):455-61. doi: 10.1016/j.radonc.2010.09.028. Radiother Oncol. 2010. PMID: 21084125
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.
Vandecasteele K, Delrue L, Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, De Meerleer G. Vandecasteele K, et al. Int J Gynecol Cancer. 2012 May;22(4):630-7. doi: 10.1097/IGC.0b013e3182428925. Int J Gynecol Cancer. 2012. PMID: 22237382
65 results